LAS VEGAS, May 7, 2020
LAS VEGAS, May 7, 2020 /PRNewswire/ -- The growth of Duchenne Muscular Dystrophy (DMD) Market is anticipated to increase because of an increasing incidence of DMD patients as well as the launch of emerging drugs in the 7MM.
DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030" to its portfolio.
Key Highlights from the report are:
Duchenne Muscular Dystrophy is a progressive form of muscular dystrophy, which usually occurs in males, though in rare cases may affect females as well, causing progressive weakness and loss (atrophy) of skeletal and heart muscles.
The disease epidemiology covered in the report proffers historical as well as forecasted Duchenne Muscular Dystrophy epidemiology, which is segmented as Diagnosed Prevalent Population of DMD, Age-specific Diagnosed Prevalence of DMD, Mutation-specific Diagnosed Prevalence of DMD and Diagnosed Prevalence of Associated Comorbidities in DMD in the 7MM market from 2017 to 2030.
The report also covers Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy, including several mutations such as Large Mutations, Small Mutations and Point Mutations with major proportion for deletions in Large Mutations subgroup.
Duchenne Muscular Dystrophy report encloses the detailed analysis of DMD marketed drugs and mid and late-stage pipeline drugs.
The therapies that are approved for the DMD treatment are Vyondys 53 (Golodirsen), Emflaza, Exondys 51, Translarna along with many more.
Drugs covered in the report are:-
There are several key players robustly involved in developing potential products such as
And many others
Key Players covered in the DMD market report are:-
And many others
The reasons for buying this report:
Table of Contents
Duchenne Muscular Dystrophy Market Overview at a Glance
DMD Disease Background and Overview
Duchenne Muscular Dystrophy Epidemiology and Patient Population
Country Wise-Epidemiology of DMD
Duchenne Muscular Dystrophy Treatment
General Guidelines on DMD
United States Guidelines on Duchenne Muscular Dystrophy
European Guidelines on Duchenne Muscular Dystrophy
DMD Marketed Drugs
Duchenne Muscular Dystrophy Emerging Drugs
Key Cross Competition
Casimersen: Sarepta Therapeutics
Puldysa (Idebenone): Santhera Pharmaceuticals
Edasalonexent: Catabasis Pharmaceuticals
Viltolarsen: Nippon Shinyaku (NS Pharma)
Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
TAS-205: Taiho Pharmaceutical
Pamrevlumab (FG-3019): FibroGen
SRP-9001: Sarepta Therapeutics
Allogeneic Cardiosphere-Derived Cells (CAP-1002): Capricor
DS-5141b: Daiichi Sankyo
Duchenne Muscular Dystrophy 7 Major Market Analysis
The United States Market Outlook
EU-5 Countries: Market Outlook
Japan: Market Outlook
SWOT Analysis for Duchenne Muscular Dystrophy
Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.